Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6661 to 6675 of 7707 results

  1. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued [GID-TAG419]

    Technology appraisal guidance
    Discontinued

  2. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued [GID-TA10233]

    Technology appraisal guidance
    Discontinued

  3. Osteoarthritis - naproxcinod [ID417]

    Discontinued [GID-TAG426]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued [GID-TA10543]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued [GID-TA10413]

    Technology appraisal guidance
    Discontinued

  6. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued [GID-TA10186]

    Technology appraisal guidance
    Discontinued

  7. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued [GID-TA10891]

    Technology appraisal guidance
    Discontinued

  8. Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]

    Discontinued [GID-TA10212]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued [GID-TA10321]

    Technology appraisal guidance
    Discontinued

  10. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

    Technology appraisal guidance
    Discontinued

  12. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued [GID-TAG444]

    Technology appraisal guidance
    Discontinued

  13. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued [GID-TAG375]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued [GID-TA10193]

    Technology appraisal guidance
    Discontinued

  15. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued [GID-TA10353]

    Technology appraisal guidance
    Discontinued